Form 4: Anil Kapur, Nurix Therapeutics Director, Reports Stock Option Grant

Director Anil Kapur reports receiving a stock option grant from Nurix Therapeutics.

Summary

• Anil Kapur, a director of Nurix Therapeutics, Inc. [NRIX], filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on May 19, 2025.
• Kapur was granted a stock option to purchase 25,000 shares of Nurix Therapeutics common stock at an exercise price of $9.51.
• The stock option vests 100% on the earlier of the next annual meeting of the Issuer's stockholders and May 19, 2026, subject to continued service.
• The option expires on May 18, 2035.
• Following the transaction, Kapur directly owns 25,000 derivative securities.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing regarding a stock option grant, indicating a neutral sentiment.

Positives

• The grant of stock options to directors can align their interests with those of shareholders.

Industry Context

Stock options are a common form of compensation for directors and executives in publicly traded companies, particularly in the biotechnology industry, to incentivize performance and align interests with shareholders.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice in publicly traded companies, especially in the biotech sector.
• The size of the grant (25,000 shares) would need to be compared to grants given to directors at comparable companies like BioNTech, Moderna, or Gilead Sciences to assess its relative significance.
• Vesting schedules tied to continued service and annual meetings are also typical.

Key Dates

Keywords

Form 4, stock option, director, NRIX, Nurix Therapeutics, beneficial ownership, Kapur, equity